Orphan Drug Congress 2012

Key Topics

-Successful development plan for Orphan Drug

-Regulatory challenges surrounding Orphan drug development

-Developing patient registries

-Commercial aspects of orphan drug development

-Patient perspective

+ PLUS

-Ms. Lise Aagaard (University of Copenhagen) will cover the important Paediatric regulatory environment in EU for Orphan Drugs

-President of OrphaNet, Ms. Segolene Ayme will present International Rare Disease Research Initiative

Treatments of rare diseases has long represented market niche in the pharmaceutical industry. Recently the importance of developing medicines for rare and obscure diseases have forced traditional pharma companies to re-evaluate their position on orphan and ultra orphan drugs. Despite the incentives relating to marketing exclusivity, taxes and fees, protocol design and research grants for the development of orphan drugs, there remain significant challenges.

Find Your Reasons To Attend

-Discuss how to improve processes for designation and approval of orphan drug

-Understand the infrastructure in order to gain approval in emerging markets

-Gain critical insights behind the successful development, authorization and reimbursement of rare disease drugs

-Find out how to regulate the use of social media for orphan drugs & rare diseases

-Explore the importance of communication Between Pharma, Patient & HTA Bodies

-Top executives and experts coming from leading pharmaceutical companies as well as from medium and small pharma companies with the focus on rare and neglected diseases: